AstraZeneca blames trial design for Phase 3 failure of bone disease drug

New details from AstraZeneca's failed Phase 3 trial of its enzyme replacement therapy for a genetic bone disease suggest the test missed its goals because of how the trial was composed, as the drugmaker seeks ...